Comparison of Autologous Conditioned Serum and Platelet-Rich Plasma Following Arthrocentesis in Temporomandibular Joint Osteoarthritis: A Randomized Clinical Trial.

Authors

Rojdan Ferman Güneş Uysal, Ibrahim Uysal

Published in

Journal of oral rehabilitation. Sep 24, 2026. Epub Sep 24, 2026.

Abstract

Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative condition that negatively affects quality of life. Although platelet-rich plasma (PRP) is widely used, its efficacy remains controversial. Autologous conditioned serum (ACS), which targets inflammation via interleukin-1 receptor antagonist (IL-1Ra), has emerged as a novel biological therapy.
To compare the effects of two autologous biological agents, PRP and ACS, used as adjuncts to arthrocentesis, on pain, maximum mouth opening (MMO) and joint sounds in patients with TMJ-OA.
This randomized, single-centre clinical trial with blinded outcome assessment and statistical analysis included 75 patients with TMJ-OA. Participants were allocated to three groups: ACS, PRP and control (n = 25 each). All patients underwent arthrocentesis; the ACS and PRP groups received 1 mL intra-articular injections, while the control group received no additional treatment. Outcomes were assessed at baseline, 1 week, 1 month, 3 months and 6 months by a blinded assessor. Pain was evaluated using a visual analogue scale (VAS), MMO was measured in millimetres and joint sounds were clinically assessed.
Baseline characteristics were comparable among the groups. From the first week onward, significant differences in VAS and MMO were observed at all follow-up time points (p < 0.001). Both ACS and PRP groups demonstrated greater improvement compared to the control group. However, no consistent statistically significant differences were observed between the two treatment groups. Joint sounds decreased significantly in both treatment groups, particularly at later follow-up periods.
Both ACS and PRP following arthrocentesis improved clinical outcomes in TMJ-OA, with no consistent superiority between treatments.
ClinicalTrials.gov: NCT06839326.

PMID:
42785962
Bibliographic data and abstract were imported from PubMed on 25 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.